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Abstract
Etoposide is one of the most successful chemotherapeutic agents used for the treatment of human
cancers. The drug kills cells by inhibiting the ability of topoisomerase II to ligate nucleic acids that
it cleaves during the double-stranded DNA passage reaction. Etoposide is composed of a polycyclic
ring system (rings A–D), a glycosidic moiety at the C4 position, and a pendant ring (E–ring) at the
C1 position. Although drug-enzyme contacts, as opposed to drug-DNA interactions, mediate the
entry of etoposide into the topoisomerase II-drug-DNA complex, the substituents on etoposide that
interact with the enzyme have not been identified. Therefore, saturation transfer difference [1H]-
nuclear magnetic resonance spectroscopy and protein-drug competition binding assays were
employed to define the groups on etoposide that associate with yeast topoisomerase II and human
topoisomerase IIα. Results indicate that the geminal protons of the A–ring, the H5 and H8 protons
of the B–ring, as well as the H2’ and H6’ protons and the 3’– and 5’–methoxyl protons of the pendent
E–ring interact with both enzymes in the binary protein-ligand complexes. In contrast, no significant
nuclear Overhauser enhancement signals arising from the C–ring, the D–ring, or the C4 glycosidic
moiety were observed with either enzyme, suggesting that there is limited or no contact between
these portions of etoposide and topoisomerase II in the binary complex. The functional importance
of E–ring substituents was confirmed by topoisomerase II-mediated DNA cleavage assays.
Etoposide is one of the most successful chemotherapeutic agents used for the treatment of
human cancers (1–4). The drug currently is in its third decade of clinical use and is front line
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therapy for a variety of malignancies, including leukemias, lymphomas, and several solid
tumors (1–4). Until the development of paclitaxel and related compounds, etoposide was the
most widely prescribed anticancer drug in the world.
The cellular target for etoposide is topoisomerase II (1–5). This essential enzyme relaxes,
unknots, and untangles DNA by passing a double helix through a transient double-stranded
break that it generates in a separate segment of DNA (6–12). Etoposide acts specifically by
inhibiting the ability of topoisomerase II to ligate DNA molecules that it has cleaved (13,14).
This drug-induced inhibition leads to the accumulation of covalent, topoisomerase II-cleaved
DNA complexes (i.e., cleavage complexes) (5). When DNA tracking enzymes such as
polymerases or helicases collide with these complexes, they convert them to permanent
enzyme-linked double-stranded breaks in the genetic material (6–12). These breaks destabilize
the genome and when present in sufficient concentrations, trigger programmed cell death
pathways (9,15–21).
Several lines of evidence indicate that interactions between topoisomerase II and etoposide, as
opposed to drug-DNA interactions, are critical for drug activity and mediate the entry of
etoposide into the ternary enzyme-drug-DNA complex. First, mutation of specific residues in
topoisomerase II dramatically affects the ability of etoposide to increase levels of enzyme-
DNA cleavage complexes (4,9,22–28). Second, etoposide binds weakly (if at all) to DNA in
the absence of topoisomerase II (29). Third, the drug binds to yeast topoisomerase II and human
topoisomerase IIα in the absence of nucleic acids and a mutant yeast enzyme (yTop2H1011Y)
that is resistant to etoposide displays a reduced binding affinity for the agent (30,31). Fourth,
etoposide displays a similar kinetic affinity for topoisomerase II-DNA cleavage complexes
formed at sites with markedly different levels of scission enhancement (32). Finally, DNA
breaks accumulate more rapidly when etoposide is incubated with topoisomerase II prior to
the addition of DNA (as compared to the opposite order of addition) (32).
Hundreds of etoposide derivatives have been analyzed in an effort to establish structure-activity
relationships within this drug class (33–42). Despite the importance of protein-drug
interactions, none of these studies have identified any of the substituents on etoposide that
interact with topoisomerase II. Therefore, the present study utilized saturation transfer
difference [1H]-nuclear magnetic resonance (STD [1H]-NMR) spectroscopy (43–47) and
protein-drug competition binding assays to define the groups on the drug that associate with
the type II enzyme. Results indicate that substituents on the A–, B–, and E–rings of etoposide
interact with yeast topoisomerase II and human topoisomerase IIα. The functional importance
of E–ring substituents was confirmed by topoisomerase II-mediated DNA cleavage assays.
EXPERIMENTAL PROCEDURES
Materials
Negatively supercoiled pBR322 plasmid DNA was prepared using a Plasmid Mega Kit
(Qiagen) as described by the manufacturer. Etoposide was purchased from Sigma. Teniposide
was provided by Bristol-Meyers Squibb. The synthesis of etoposide derivatives with modified
E-ring substituents will be described elsewhere. TOP-53 was provided as a dichloride salt by
Taiho Pharmaceuticals. All drugs were stored at 4 ° C as 20 mM stock solutions in 100%
DMSO. Drugs used for NMR experiments were stored in 100% d-DMSO. [3H]etoposide was
obtained from Moravek Biochemicals as a 1.5 mM stock in 100% ethanol. D2O (99.9%) was
purchased from Aldrich. All other chemicals were analytical reagent grade.
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Purification of Type II Topoisomerases
Highly concentrated yeast topoisomerase II and human topoisomerase IIα were expressed in
Saccharomyces cerevisiae and purified as described (26,48,49). The yeast and human enzymes
were purified from 50–60 g of frozen wet-packed yeast JEL 1 cells transformed with
YEpGAL1TOP or YEpWOB6, respectively. In the final step of the purification, the type II
topoisomerases were eluted from phosphocellulose columns (P81, Whatman) with buffer
containing 10 mM sodium phosphate, pH 7.7, 750 mM KCl, 1 mM EDTA, 1 mM EGTA, 0.5
mM dithiothreitol, and 5% d-glycerol in D2O. Typical yields exceeded 1 mg of yeast
topoisomerase II or 0.2 mg of human topoisomerase IIα per g of wet-packed yeast cells.
Cleavage of Plasmid DNA by Yeast Topoisomerase II
DNA cleavage reactions were carried out as described (26). Reaction mixtures contained 150
nM yeast topoisomerase II and 5 µM negatively supercoiled pBR322 in a total of 20 µL of 10
mM sodium phosphate, pH 7.7, 100 mM KCl, 0.1 mM NaEDTA, 5 mM MgCl2 containing
etoposide, teniposide, TOP-53, hydroxyphenyl-etoposide, or phenyl-etoposide (up to 300 µM)
solubilized in 100% DMSO (all reactions contained 10% DMSO final concentration). DNA
cleavage was initiated by the addition of enzyme and reaction mixtures were incubated for 6
min at 28 °C to establish DNA cleavage/religation equilibria. Cleavage complexes were
trapped by the addition of 2 µL of 5% SDS and 1.5 µL of 250 mM NaEDTA, pH 8.0. Proteinase
K was added (2 µL of 0.8 mg/mL) and reaction mixtures were incubated for 30 min at 45 °C
to digest the topoisomerase II. Samples were mixed with 2 µL of 30% sucrose, 0.5%
bromophebol blue, and 0.5% xylene cyanol FF in 10 mM Tris-HCl, pH 7.9, heated for 2 min
at 45 °C, and subjected to electrophoresis in a 1% agarose gel in 40 mM Tris-acetate, 2 mM
NaEDTA containing 0.5 µg/mL ethidium bromide. Cleavage was monitored by the conversion
of negatively supercoiled DNA to linear molecules. DNA was visualized by medium
wavelength UV light and quantified using an Alpha Innotech digital imaging system.
STD [1H]-NMR Spectroscopy
All NMR experiments are performed at 283 K using a Bruker Avance DRX 500-MHz
spectrometer equipped with a 5-mm BBI probe. NMR buffers were prepared in 99.9% D2O
and contained 10 mM sodium phosphate, pH 7.7, 250 mM KCl, 0.1 mM Na2EDTA, and 5 mM
MgCl2. NMR samples (500 µL) contained 5 µM yeast topoisomerase II or human
topoisomerase IIα and 100–400 µM etoposide or selected analogs, and were maintained at 5 °
C until data were obtained. STD-NMR experiments employed a pulse scheme similar to that
reported by Mayer and Meyer (46). The gradient pulse that was applied was 1 ms at 30% with
a 500 µs recovery delay. The water signal was suppressed by tailoring a watergate pulse
sequence to the beginning of the f2 presaturation STD-pulse program. For each experiment
(on and off resonance irradiation), a total of 2000 scans were collected with a 3 s relaxation
delay between each scan. On and off-resonance irradiations were performed at 0.5 and 17 ppm,
respectively. Difference spectra were prepared by subtracting the on-resonance spectrum from
the off-resonance spectrum. Signals resulting in the difference spectrum represent the NOE
difference signals generated by the transfer of irradiation energy from the enzyme to the bound
ligand. Ligand protons in close spatial proximity with the enzyme displayed larger NOE
signals. Mapping of the NOE signals with their proton assignments on the ligand revealed the
ligand binding epitope to the target topoisomerase II. Spectra were processed using Bruker
XWINNMR (v3.2) software.
Topoisomerase II-Drug Binding
Competition binding studies were performed using a nitrocellulose filter binding technique.
Nitrocellulose membranes (0.45 µm HA; Millipore) were soaked in binding buffer (10 mM
sodium phosphate, pH 7.7, 250 mM KCl, 0.1 mM NaEDTA, and 5 mM MgCl2) for 10 min.
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Reaction mixtures contained 1.6 µM yeast topoisomerase II and 20 µM [3H]etoposide, as well
as 0–100 µM etoposide, TOP-53, hydroxyphenyl-etoposide or phenyl-etoposide in a total of
60 µL of binding buffer. Samples were incubated for 6 min at 30 °C and applied to the
nitrocellulose membranes in vacuo. Filters were immediately washed three times with 1 mL
of ice-cold binding buffer, dried, and submerged in 8 mL of scintillation fluid (Econo-Safe;
Research Products International). Radioactivity remaining on membranes was quantified using
a Beckman LS 5000 TD scintillation counter. The amount of radioactive etoposide remaining
on the filter in the absence of enzyme was subtracted prior to binding calculations.
RESULTS
Interaction of Etoposide with Topoisomerase II
Etoposide, a semisynthetic derivative of podophyllotoxin, is an important anticancer agent
(1–4). It is composed of a polycyclic ring system (rings A–D), a glycosidic moiety at the C4
position, and a pendant ring (E–ring) at the C1 position (Figure 1) (1–4). The drug kills cells
by inhibiting the ability of topoisomerase II to ligate nucleic acids that it cleaves during the
double-stranded DNA passage reaction (13,14). As a result of etoposide action, high levels of
topoisomerase II-associated DNA breaks accumulate in treated cells (1–5). The effects of
etoposide on DNA cleavage mediated by yeast topoisomerase II are shown in Figure 2.
In an effort to identify the substituents that influence drug activity, numerous derivatives of
etoposide have been synthesized (33–42). Most of the modifications have focused on the
glycosidic moiety and the E–ring (35,37–40). Many of these changes have profound effects
on the cellular activity of etoposide. However, for most substitutions, it is not known whether
alterations in drug potency or efficacy are caused by changes in drug uptake/efflux or
metabolism, as opposed to a direct effect on topoisomerase II-mediated DNA ligation. Even
in the small number of cases in which the effects of drug derivatives on the purified enzyme
have been assessed, it has not been possible to ascribe a specific function to any given
substitutent on etoposide (35,39,40).
Given the wide clinical use of etoposide, it is important to understand how the drug interacts
with its protein target. Therefore, STD [1H]-NMR spectroscopy (43–47) was employed to
identify the substituents on etoposide that interact with topoisomerase II. Since drug-enzyme
contacts, as opposed to drug-DNA interactions, mediate the entry of etoposide into the
topoisomerase II-drug-DNA complex (4,9,22–32), the present study focused on interactions
between etoposide and topoisomerase II in the binary protein-ligand complex.
In the STD [1H]-NMR technique (43–47), topoisomerase II is selectively saturated with
magnetization by irradiating the sample at a frequency at which no drug protons resonate (on-
resonance frequency). Magnetization is spread very rapidly throughout the protein by
intramolecular spin diffusion. Substituents on the drug (i.e., ligand) that interact with
topoisomerase II are progressively saturated with magnetization via intermolecular, through-
space, dipole-dipole interactions. The NMR spectrum generated following on-resonance
irradiation is subtracted from an off-resonance (or reference) spectrum. This off-resonance
spectrum is taken following saturation of the sample with a magnetization frequency that is
different from the resonance frequencies of either topoisomerase II or the drug. The resulting
difference spectrum contains only the signals of the drug substituents that interact with the
enzyme and are saturated through the intermolecular transfer of magnetization from the protein
(43–47).
NMR samples contained 5 µM yeast topoisomerase II and 200 µM drug, and spectra were
recorded at 15 °C. The buffer used for spectroscopy contained 10 mM sodium phosphate and
250 mM KCl, as opposed to 10 mM Tris-Cl and 100 mM KCl, which generally is used to assess
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topoisomerase II-mediated DNA cleavage (26). The use of phosphate eliminated the proton
spectrum of the Tris buffer, which overwhelmed many of the drug peaks. In addition, the
increased salt was required in order to maintain enzyme solubility at the high protein
concentration and low temperature used for NMR. As seen in Figure 2, topoisomerase II
maintained high DNA cleavage activity in the NMR buffer. Under the experimental conditions
employed, enzyme-drug samples were stable for at least 24 h as assessed by NMR spectroscopy
and DNA cleavage assays (data not shown).
As a prelude to STD [1H]-NMR experiments, proton resonances of etoposide were assigned
by 1-D NMR analysis (50) (a spectrum that includes these assignments is shown in
supplemental Figure S1). A representative STD [1H]-NMR experiment that analyzed the
binding of etoposide to yeast topoisomerase II is shown in Figure 3. The difference spectrum,
which reveals the nuclear Overhauser enhancment (NOE) signals from the bound drug, is seen
at the top. Results indicate that substituents on the A–, B–, and E–rings interact with
topoisomerase II in the binary protein-ligand complex. More specifically, NOE signals were
observed for the geminal protons of the A–ring (6.0 ppm), the H5 and H8 protons of the B–
ring (7.0 and 6.6 ppm, respectively), as well as the H2’ and H6’ protons (6.4 ppm) and the 3’–
and 5’–methoxyl protons of the pendent E–ring (3.8 ppm). In contrast, no significant NOE
signals arising from the C–ring, the D–ring, or the C4 glycosidic moiety were observed,
suggesting that there is limited or no contact between these portions of etoposide and the
enzyme in the binary complex.
One caveat should be noted, however. Resonances for the three hydroxyl groups present in
etoposide, the 2”–OH and 3”–OH of the glycosidic moiety and the 4’–OH of the E–ring, were
obscured by the water peak and could not be visualized in any of the NMR spectra.
To determine whether conclusions based on yeast topoisomerase II could be extended to
mammalian systems, interactions between etoposide and human topoisomerase IIα were
analyzed by STD [1H]-NMR spectroscopy. The NOE signals in the difference spectrum
generated for the binary topoisomerase IIα–etoposide complex were similar to those described
above for yeast topoisomerase II (Figure 3, third spectrum from top). Thus, it appears that the
same etoposide substituents that interact with yeast topoisomerase II also interact with the
human enzyme.
C4 Substituents
On the basis of the STD [1H]-NMR data, it appears that the glycosidic moiety of etoposide,
which is attached to the C–ring at the C4 position, does not interact with yeast topoisomerase
II or human topoisomerase IIα in the binary enzyme-drug complex. To characterize the effects
of alternative substituents at the C4 position, interactions between the yeast enzyme and two
etoposide derivatives were characterized by STD [1H]-NMR. The first was teniposide, which,
like etoposide, also is in clinical use (1,2). Teniposide contains the C4 substituent of etoposide,
except that the 8”-methyl group is replaced by a thiophene moiety (see Figure 1). In all other
respects, the two compounds are identical. NMR signals derived from the 8”-thiophene protons
are shifted well downfield to a region of the spectrum that is devoid of protein peaks (6.96–
7.37 ppm). Although teniposide is ~10–fold more potent than etoposide in human cells, the
two drugs are equipotent in purified systems (see Figure 2). Thus, it is believed that the effects
of the thiophene moiety are primarily physiological (uptake, metabolism, etc.) in nature (1,2).
As seen in Figure 4 (top spectrum), difference spectrum NOE signals from the A–, B–, and E–
ring substituents of teniposide were similar to those of etoposide. In addition, no NOE signals
from the glycosidic protons of the three thiophene protons were observed. These findings
suggest that the C4 glycosidic moieties of etoposide and teniposide do not interact with
topoisomerase II in the drug-enzyme complex. In support of this conclusion, the ability of
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etoposide and teniposide to enhance topoisomerase II-mediated DNA cleavage is identical (see
Figure 2), despite the difference in the 8”-substituents of these two drugs.
The second derivative that was assessed was TOP-53. In contrast to etoposide and teniposide,
TOP-53 contains a flexible dicationic amino-alkyl chain at the C4 position (see Figure 1)
(51). Although TOP-53 is structurally identical to these compounds at all other positions, it
exhibits a significantly greater ability (~4–fold higher potency) to stimulate DNA cleavage
mediated by yeast (see Figure 2) or human type II topoisomerases (52). This finding implies
that substituents at the C4 position have the capacity to alter drug actions in the ternary complex.
Therefore, to determine whether the presence of the amino-alkyl chain of TOP-53 affects the
interaction of the drug with the enzyme, drug-topoisomerase II interactions were assessed by
STD [1H]-NMR.
As found for etoposide and teniposide, NOE signals were observed for the geminal protons of
the A–ring, the H5 and H8 protons of the B–ring, as well as the H2’ and H6’ protons and the
3’– and 5’–methoxyl protons of the pendent E–ring (Figure 4, third spectrum from top).
However, the NOE signals for all of these positions on TOP-53 were ~2-fold stronger than
those observed for the other podophyllotoxins. In addition, NOE signals for every CH2 group
of the amino-alkyl side chain of TOP-53 (2.27–3.05 ppm) were observed (Figure 4).
These findings suggest that TOP-53 binds to yeast topoisomerase II more tightly or with a
closer geometry than does etoposide. Unfortunately, the STD [1H]-NMR technique employed
cannot distinguish between these two possibilities. Therefore, nitrocellulose filter binding
competition assays were utilized to address this issue. In these experiments, the ability of non-
radioactive etoposide and TOP-53 to compete with [3H]etoposide for binding to yeast
topoisomerase II was determined. As seen in Figure 5, the concentration of TOP-53 that was
required to displace ~50% of the bound [3H]etoposide was ~4–fold lower than needed by
etoposide. These data demonstrate that the affinity of TOP-53 for topoisomerase II is greater
than that of etoposide, and likely accounts for the enhanced potency of the etoposide derivative.
Furthermore, they imply that this enhanced binding is due to the presence of the additional
contacts between the C4 amino-alkyl moiety of TOP-53 and the enzyme that were identified
by STD [1H]-NMR.
E–Ring Substituents
Early structure-activity studies suggested that E–ring substituents on etoposide were important
for drug function against mammalian type II topoisomerases (35,39,40). As seen in Figure 2,
this conclusion was confirmed for drug-induced DNA cleavage by yeast topoisomerase II.
Removal of the 3’- and 5’-methoxyl groups from the E–ring of etoposide (hydroxyphenyl-
etoposide; see Figures 1 and 2) decreased drug activity ~60%. Further removal of the 4’-
hydroxyl group (phenyl-etoposide; see Figures 1 and 2), decreased drug activity to nearly
baseline.
The NMR experiments discussed above indicate that the E–ring of etoposide is intimately
associated with topoisomerase II in the binary complex. Therefore, the effects of the 3’- and
5’-methoxyl, and the 4’-hydroxyl substituents on the interaction between etoposide and yeast
topoisomerase II were monitored by STD [1H]-NMR. NOE signals for the E–ring H2’ and H6’
protons were observed for hydroxyphenyl-etoposide and phenyl-etoposide (Figure 6, top and
third spectra, respectively). In addition, signals were observed for the H3’ and H5’ protons that
replaced the corresponding methoxyl substituents in hydroxyphenyl-etoposide and phenyl-
etoposide and the H4’ proton that replaced the hydroxyl group in phenyl-etoposide. As
observed for etoposide, the only other NOE signals seen corresponded to the geminal protons
of the A–ring and the H5 and H8 protons of the B–ring. It should be noted that NOE signals
for both drug derivatives were somewhat diminished as compared to the parent compound.
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The NMR results indicate that despite the loss of critical substituents, the pendant E–rings of
hydroxyphenyl-etoposide and phenyl-etoposide still maintain a close association with
topoisomerase II in the binary complex. This finding suggests that the 3’– and 5’–methoxyl
groups and the 4’-hydroxyl of the E–ring are not required for drug binding. Therefore,
nitrocellulose filter binding competition assays were employed to further define the
contribution of these groups to drug binding. As seen in Figure 5, the ability of hydroxyphenyl-
etoposide and phenyl-etoposide to compete with [3H]etoposide for binding to yeast
topoisomerase II was similar to that of etoposide. On the basis of these results, we conclude
that the 3’– and 5’– methoxyl groups and the 4’–hydroxyl of the etoposide E–ring play critical
functional roles for drug action, but do not mediate binding of the drug to the type II enzyme.
DISCUSSION
Although etoposide is one of the most widely prescribed drugs used for the treatment of human
cancers (1–4), the specific ring substituents that mediate its interactions with topoisomerase II
have been impossible to define. However, the use of STD [1H]-NMR has enabled drug-enzyme
interactions to be characterized at the proton level. Results indicate that protons on the A–ring,
B–ring, and pendent E–ring are in close contact with yeast topoisomerase II and human
topoisomerase IIα in the binary enzyme-ligand complex. These findings are summarized in
Figure 7, which highlights hydrogens that interact with topoisomerase II in red and those for
which no interactions were observed in green.
It has long been known that the glycosidic moiety of etoposide plays important physiological
roles (1–4). The presence of this group keeps etoposide from interacting with tubulin and
substitution of a thiophene for the 8”–methyl alters cellular uptake of the drug. Beyond these
physiological functions, it is not clear whether the glycosidic moiety of etoposide plays any
direct role in enhancing topoisomerase II-mediated DNA cleavage. To this point, no contacts
were observed between topoisomerase II and any glycosidic protons and substitution of the
thiophene at the 8” position had no effect on DNA scission. It is notable, however, that
substitution of the glycosidic moiety with a flexible and charged amino-alkyl side chain, as in
TOP-53, significantly enhanced drug-enzyme binding and drug activity against topoisomerase
II. Furthermore, contacts were observed between the enzyme and every observable proton of
this side chain in the binary complex. Therefore, while the C–4 glycosidic moiety does not
appear to mediate interactions between etoposide and topoisomerase II, other substituents at
this position have the capacity to influence drug actions against its enzyme target.
Previous studies indicate that E–ring substituents are important for etoposide function (35,
37,39,40). Indeed, as seen in Figure 2, removal of the 3’– and 5’–methoxyl groups or the 4’–
hydroxyl moiety significantly impairs the ability of etoposide to enhance DNA cleavage
mediated by yeast topoisomerase II. As determined by STD [1H]-NMR, every substituent on
the E–ring is intimately associated with the protein in the binary complex. Since the E–ring
has free rotation about the 1’–linkage to the C–ring, the H2’ and H6’ protons, as well as the
3’– and 5’–methoxyl groups are chemically equivalent and cannot be distinguished by NMR.
A previous study by Long and co-workers found that removal of one of the two methoxyl
groups had no obvious effect on levels of DNA scission (37). Thus, as shown in the shaded
region in Figure 7, we propose that contacts between etoposide and topoisomerase II extend
to only a portion of the E–ring.
Although the 3’–methoxyl, 5’–methoxyl, and 4’–hydroxyl moieties of the E–ring all are
important for etoposide function (35,39,40), none of them appear to contribute significantly to
drug-enzyme binding. In fact, when these groups were replaced with hydrogen atoms, NOE
signals were observed by STD [1H]-NMR for all of the resulting protons. This finding suggests
that protein associations with the E–ring may be mediated by stacking interactions rather than
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any specific group on the ring. In the absence of additional structural information, it is not
known whether the 3’–methoxyl, 5’–methoxyl, or 4’–hydroxyl groups contribute to drug
function through direct interactions with individual amino acids in topoisomerase II, or by
subtly changing the overall geometry of the etoposide-enzyme-DNA complex.
In the absence of topoisomerase II, etoposide exhibits little if any ability to bind to DNA
(29). However, the fact that the drug displays a DNA cleavage site specificity (preferring a
cytosine at the base immediately 5’ to the scissile bond (5,53) implies that etoposide interacts
with DNA in the ternary topoisomerase II-drug-nucleic acid complex. If this is the case, which
portions of etoposide contact DNA in the active site of topoisomerase II? Given the strong
contacts between the enzyme and the A–, B–, and E–rings we believe that these portions of
the drug are unlikely to interact with DNA. Furthermore, substitution of a thiophene for the
8”–methyl in teniposide or an amino alkyl chain in TOP-53 does not alter the DNA cleavage
specificity of etoposide, and the amino alkyl substitution at the C4 position interacts strongly
with topoisomerase II (5,52,53). Consequently, we also believe that the glycoside moiety of
etoposide probably does not contact DNA. Therefore, we propose that if any portions of
etoposide interact with DNA in the active site of topoisomerase II, the C– and D–rings are the
most likely candidates. Future studies with the ternary enzyme-drug-DNA complex will be
required to address this hypothesis directly.
Finally, it should be noted that there is a strong correlation between results obtained from STD
[1H]-NMR experiments and DNA cleavage assays. Alterations in etoposide substituents that
contact the enzyme in the binary complex diminished the ability of the drug to enhance
topoisomerase II-mediated DNA cleavage. Conversely, alterations in drug substituents that
increased the number of contacts between the enzyme and etoposide raised levels of DNA
scission. Therefore, STD [1H]-NMR results with the binary enzyme-drug complex appear to
have predictive value that may contribute to the future development of etoposide derivatives
with greater activity against topoisomerase II.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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FIGURE 1.
Structures of etoposide and etoposide derivatives with C4 or C1 (E–ring) substitutions that
were employed in the present study.
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FIGURE 2.
Etoposide derivatives stimulate DNA cleavage mediated by yeast topoisomerase II. Levels of
DNA cleavage were expressed as a fold–enhancement over reactions that were carried out in
the absence of drug. Cleavage titrations using etoposide derivatives with C4 substitutions (left
panel) or E–ring substitutions (right panel) are shown. Left: Assay mixtures contained 0–200
µM etoposide (open circles) or teniposide (closed circles), or 0–100 µM TOP-53 (open
squares). Higher concentrations of TOP-53 generated multiple cleavage events per plasmid
and therefore are not shown. Right: Assay mixtures contained 0–300 µM etoposide (open
circles), hydroxyphenyl-etoposide (closed circles), or phenyl-etoposide (open squares). Error
bars represent the standard deviation of three independent experiments. Insets show cleavage
reactions carried out in cleavage buffer containing 100 mM KCl (filled bars) or 250 mM KCl
(open bars) the presence of 200 µM etoposide (Etop), teniposide (Tenip), hydroxyphenyl-
etoposide (HO-φ-etop), or phenyl-etoposide (φ-etop), or 100 µM TOP-53 (TOP).
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FIGURE 3.
Interaction of etoposide with yeast topoisomerase II and human topoisomerase IIα as
determined by STD [1H]-NMR spectroscopy. 1D [1H]-NMR reference spectra of etoposide
are shown in the second and fourth spectrum from the top. 1D STD [1H]-NMR spectra of
etoposide in the presence of yeast topoisomerase II (top spectrum) or human topoisomerase
IIα (third spectrum from top) also are shown. Spectra are representative of at least three
independent experiments.
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FIGURE 4.
Interaction of teniposide and TOP-53 with yeast type II topoisomerase as determined by STD
[1H]-NMR spectroscopy. 1D [1H]-NMR reference spectra of teniposide (second spectrum
from top) and TOP-53 (fourth spectrum from top) are shown. 1D STD [1H]-NMR spectra of
teniposide (top spectrum) and TOP-53 (third spectrum from top) in the presence of yeast
topoisomerase II also are shown. Spectra are representative of at least three independent
experiments.
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FIGURE 5.
Binding of etoposide and derivatives to yeast topoisomerase II. Left: Reaction mixtures
contained 20 µM [3H]etoposide and 0–100 µM etoposide (open circles) or TOP-53 (closed
circles). Right: Reaction mixtures contained 20 µM [3H]etoposide and 0–100 µM etoposide
(open circles), hydroxyphenyl-etoposide (closed circles), or phenyl-etoposide (open squares).
Levels of [3H]etoposide binding to yeast topoisomerase II observed in the absence of
competitor drug were set to 1. Error bars represent the standard deviation of three independent
experiments.
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FIGURE 6.
Interaction of hydroxyphenyl-etoposide and phenyl-etoposide with yeast type II topoisomerase
as determined by STD [1H]-NMR spectroscopy. 1D [1H]-NMR reference spectra of
hydroxyphenyl-etoposide (second spectrum from top) and phenyl-etoposide (fourth spectrum
from top) are shown. 1D STD [1H]-NMR spectra of hydroxyphenyl-etoposide (top spectrum)
and phenyl-etoposide (third spectrum from top) in the presence of yeast topoisomerase II also
are shown. Spectra are representative of at least three independent experiments.
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FIGURE 7.
Summary of etoposide substituents that interact with type II topoisomerases. Protons that
interact with the enzyme are shown in red, those that do not are shown in green. Hydroxyl
protons that were obscured by the water peak and could not be visualized are indicated in black.
The shaded region on etoposide, including portions of the A–, B– and E–rings, is proposed to
interact with topoisomerase II in the binary drug-enzyme complex.
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